N-MOmentum - study design for a placebo-controlled study of MEDI-551 in neuromyelitis optica

被引：0
|
作者：
Cree, B. A. C. [1 ]
Bennett, J. L. [2 ]
Hartung, H. -P. [3 ]
Aktas, O. [3 ]
Kim, H. J. [4 ,5 ]
Paul, F. [6 ]
Pittock, S. [7 ]
Weinshenker, B. [7 ]
Wingerchuk, D. [8 ]
Marignier, R. [9 ]
Fujihara, K. [10 ]
Cutter, G. [11 ]
Flor, A. [12 ]
Barron, G. [13 ]
Patra, K. [12 ]
Madani, S. [12 ]
Katz, E. [13 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] Univ Dusseldorf, Dusseldorf, Germany
[4] Res Inst, Seoul, South Korea
[5] Natl Canc Ctr Hosp, Seoul, South Korea
[6] Charite, D-13353 Berlin, Germany
[7] Mayo Clin, Rochester, MN USA
[8] Mayo Clin, Scottsdale, AZ USA
[9] Lyon Univ Hosp, Lyon, France
[10] Tohoku Univ, Sendai, Miyagi 980, Japan
[11] Univ Alabama Birmingham, Birmingham, AL USA
[12] MedImmune, Gaithersburg, MD USA
[13] MedImmune, Cambridge, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1349
引用
收藏
页码：705 / 706
页数：2
相关论文
共 50 条
  • [11] Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study
    Flanagan, Eoin P.
    Levy, Michael
    Katz, Eliezer
    Cimbora, Daniel
    Drappa, Jorn
    Mealy, Maureen A.
    She, Dewei
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [12] SAFETY AND TOLERABILITY OF MEDI-551 IN SUBJECTS WITH SYSTEMIC SCLEROSIS (SSC): RESULTS FROM A PHASE 1 RANDOMIZED, PLACEBO-CONTROLLED ESCALATING SINGLE-DOSE STUDY
    Schiopu, E.
    Chatterjee, S.
    Hsu, V.
    Flor, A.
    Pavlovic, D.
    Patra, K.
    Li, J.
    McKeever, K.
    Herbst, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 562 - 562
  • [13] Placebo-controlled study in neuromyelitis optica-Ethical and design considerations (vol 22, pg 862, 2016)
    Cree, B. C.
    Bennett, J. L.
    Sheehan, M.
    Hartung, Hans-Peter
    Aktas, Orhan
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (12) : NP8 - NP8
  • [14] Safety and tolerability of MEDI-551 in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
    Agius, M.
    Klodowska-Duda, G.
    Maciejowski, M.
    Potemkowski, A.
    Sweeny, S.
    Li, J.
    Yao, W.
    Patra, K.
    Ratchford, J. N.
    Katz, E.
    Flor, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 235 - 236
  • [15] Quiescent mri activity in neuromyelitis optica spectrum disorder: results from the n-momentum randomized placebo-controlled trial: on-demand eposters p0001-p0286
    Paul, F.
    Wingerchuk, D.
    Weinshenker, B.
    Bennett, J.
    Kim, H. J.
    Pittock, S.
    Fujihara, K.
    Cutter, G.
    Marignier, R.
    Aktas, O.
    Hartung, H. P.
    Green, A.
    Drappa, J.
    Smith, M.
    Rees, W.
    Ratchford, J.
    She, D.
    Cimbora, D.
    Stefani-Hunyady, D.
    Katz, E.
    Cree, B.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 230 - 230
  • [16] Elevated Serum Glial Fibrillary Acidic Protein (sGFAP) is Associated With Increased Risk of Neuromyelitis Optica Spectrum Disorder Attacks in the N-Momentum Randomized, Masked, Placebo-Controlled Clinical Trial of Inebilizumab
    Aktas, O.
    Smith, M. A.
    Rees, W.
    Fujihara, K.
    Paul, F.
    Hartung, H-P
    Marignier, R.
    Bennett, J. L.
    Kim, H. J.
    Weinshenker, B. G.
    Pittock, S. J.
    Wingerchuk, D.
    Cutter, G.
    Green, A.
    Mealy, M. A.
    Drappa, J.
    Barron, G.
    Madani, S.
    Wang, L.
    She, D.
    Cimbora, D.
    Ratchford, J. N.
    Katz, E.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP42 - NP43
  • [17] Elevated serum glial fibrillary acidic protein (sGFAP) is associated with increased risk of neuromyelitis optica spectrum disorder attacks in the N-MOmentum randomised, masked, placebo-controlled clinical trial of inebilizumab
    Aktas, O.
    Smith, M.
    Rees, W.
    Fujihara, K.
    Paul, F.
    Hartung, H. -P.
    Marignier, R.
    Bennett, J.
    Kim, H. J.
    Weinshenker, B.
    Pittock, S.
    Wingerchuk, D.
    Cutter, G.
    Green, A.
    Mealy, M.
    Drappa, J.
    Barron, G.
    Madani, S.
    Wang, L.
    She, D.
    Cimbora, D.
    Ratchford, J.
    Katz, E.
    Cree, B.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 901 - 902
  • [18] Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
    Elena Schiopu
    Soumya Chatterjee
    Vivien Hsu
    Armando Flor
    Daniel Cimbora
    Kaushik Patra
    Wenliang Yao
    Jing Li
    Katie Streicher
    Kathleen McKeever
    Barbara White
    Eliezer Katz
    Jorn Drappa
    Sarah Sweeny
    Ronald Herbst
    Arthritis Research & Therapy, 18
  • [19] Long term safety outcomes with inebilizumab treatment in neuromyelitis optica spectrum disorder: the N-MOmentum trial
    Cree, B.
    Bennett, J.
    Weinshenker, B.
    Wingerchuk, D.
    Paul, F.
    Kim, H.
    Pittock, S.
    Fujihara, K.
    Cutter, G.
    Marignier, R.
    Aktas, O.
    Hartung, H.
    Green, A.
    Drappa, J.
    She, D.
    Cimbora, D.
    Rees, W.
    Ratchford, J.
    Katz, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 176 - 176
  • [20] Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
    Schiopu, Elena
    Chatterjee, Soumya
    Hsu, Vivien
    Flor, Armando
    Cimbora, Daniel
    Patra, Kaushik
    Yao, Wenliang
    Li, Jing
    Streicher, Katie
    McKeever, Kathleen
    White, Barbara
    Katz, Eliezer
    Drappa, Jorn
    Sweeny, Sarah
    Herbst, Ronald
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
12345